Equipment & Lab Build Checklist

A PCR business is an equipment-and-consumables business before it is anything else. "PCR technologies" is the family of nucleic-acid amplification methods (conventional PCR, real-time quantitative PCR or qPCR, and digital PCR or dPCR) used to detect and quantify DNA and RNA. Whether you are opening a clinical molecular-diagnostics lab, a contract-research service, or a food-and-water testing operation, the same physical backbone shows up in the plan. Real-time PCR alone accounts for roughly 62.78% of the global market in 2026, according to Fortune Business Insights, 2026, so most plans are built around a qPCR core with dPCR added for high-sensitivity work.

Before you write a single financial assumption, price the bench. The list below is the minimum a high-complexity setup needs, with realistic 2026 price bands drawn from instrument resellers and lab-setup guides.

• qPCR / real-time thermocycler: $3K–$30K new per unit (Unicorn Lifescience pricing); reference labs run several. Certified-refurbished units list $750–$15K on LabX with optical re-qualification and a 6–12 month warranty.
• Digital PCR (dPCR/ddPCR) platform: $80K–$250K, added when you need absolute quantification (low viral load, copy-number, AAV vector QC).
• Class II biosafety cabinet(s): $8K–$18K each, one per workflow zone to keep extraction, master-mix prep, and amplification physically separated.
• Automated nucleic-acid extraction / liquid handler: $25K–$120K, the single biggest throughput lever once daily volume passes ~80 samples.
• Centrifuges, microcentrifuge, vortex mixer, −20°C and −80°C freezers: $12K–$45K combined.
• LIMS and instrument data integration: $12K–$70K to capture results, chain of custody, and reporting that an auditor will check.
• Unidirectional clean-zone fit-out: separate rooms or hoods for reagent prep, sample prep, and amplification to control amplicon contamination, which is the failure mode that quietly destroys data quality.

One operational PCR lab cited in industry guidance was staffed by two specialists, three scientific officers, and seven medical lab technologists, with hardware alone near £61.5K (about $77K). Use that as a sanity check: instruments are a minority of true setup cost once fit-out, accreditation, validation, and six months of qualified payroll are added.

What It Costs to Open a PCR Lab

Opening a credible PCR and molecular-diagnostics operation typically runs $180K to $1.2M (£145K to £950K), depending on whether you launch a lean single-vertical lab or a multi-platform reference lab able to bill clinical payers. The wide band is real: a research-only qPCR service that never touches patient samples can start near the floor, while a CLIA high-complexity clinical lab carries accreditation, validation, and director-level payroll that push it toward the ceiling.

Cost Breakdown

• Thermocyclers, qPCR and dPCR instruments: $30K–$280K (£24K–£220K)
• Lab fit-out, clean rooms, biosafety cabinets, unidirectional workflow: $45K–$320K (£36K–£255K)
• CLIA or UKAS accreditation plus assay validation: $15K–$90K (£12K–£72K)
• Opening reagents, master mixes, primers and probes, consumables: $20K–$110K (£16K–£88K)
• LIMS, instrument software, data integration: $12K–$70K (£10K–£55K)
• Qualified laboratory director and technologists, first six months: $55K–$310K (£44K–£250K)
• Quality systems, proficiency testing, insurance, working capital: $10K–$60K (£8K–£48K)

Funding Routes

In the US, an SBA 7(a) loan (up to $5M) is the most common route for an accredited lab with contracted payer revenue, and lenders treat instrument purchases as collateralisable, which strengthens the application. SBA 504 loans suit owner-occupied lab real estate and large fixed equipment. Diagnostics startups with novel assays also raise through life-science angel syndicates, NIH SBIR/STTR grants, and instrument vendor leasing that keeps the qPCR fleet off the opening balance sheet. In the UK, Start Up Loans (up to £25,000 at 6% fixed) cover early working capital, while Innovate UK grants, commercial equipment finance, and EIS/SEIS investment are the realistic routes for the larger capital a clinical lab needs. Most founders blend an instrument lease, a working-capital loan, and equity so that the first inspection-ready quarter is funded before billing can start.

What Lenders Want, and a Pitch You Can Adapt

What an SBA lender wants to see

For a US PCR lab, the SBA 7(a) loan is the workhorse route, and the application succeeds or fails on a few specifics. Lenders want the equipment itemised, because instruments are collateral that de-risks the loan. They want a debt-service-coverage projection that survives a slow ramp, not just the optimistic case. They want the accreditation timeline on the same page as the cash-flow forecast, so they can see exactly when reimbursement begins and confirm the working-capital line carries payroll until then. And they want a management team that pairs scientific credibility with someone who has run a billing-and-operations function before. A plan that presents these four things in lender language converts far better than one that leads with the science. The same logic applies to UK Start Up Loans and Innovate UK grant applications: assessors reward a credible path to revenue over technical novelty alone.

A one-paragraph investor pitch

The point of the template is that every bracketed figure is forced to come from the financial model, so the pitch and the numbers can never drift apart. Investors notice when they do.

Instrument & Reagent Suppliers

Reagents and consumables make up about 85.63% of all PCR market revenue in 2026 (Fortune Business Insights, 2026), which is the most important number in your operating model: the instrument is bought once, but you buy reagents every working day for the life of the lab. Vendor choice locks in that recurring cost, so the plan should name the platform and the consumable strategy, not just "PCR equipment".

• Thermo Fisher Scientific — QuantStudio and Applied Biosystems qPCR systems, plus the QuantStudio Absolute Q digital PCR platform. The broadest reagent catalogue, which is both a convenience and a lock-in risk.
• Bio-Rad Laboratories — droplet digital PCR (ddPCR) leader; in February 2025 it announced a binding offer to acquire Stilla Technologies and launched a ddPCR kit for AAV capsid QC, signalling where dPCR demand is heading.
• QIAGEN — the Rotor-Gene Q rotary qPCR system and a deep sample-prep and extraction-kit line, useful when extraction is your throughput bottleneck.
• F. Hoffmann-La Roche — LightCycler and cobas platforms with clinical credibility in hospitals and reference labs, often the default for regulated diagnostic workflows.
• Agilent Technologies — instruments, reagents, and quality-control consumables; named among the top players by market analysts.
• Stilla Technologies — the Naica digital PCR system, a route to multiplex dPCR for labs that want an alternative to the incumbents.

A defensible plan negotiates reagent pricing against committed volume, qualifies a second source for critical consumables, and models the consumable cost per reaction (commonly $4–$9 for routine qPCR) rather than assuming a flat figure. That single line, multiplied by daily test volume, is what decides whether the lab actually earns the margin the projections promise.

Accreditation & Legal Requirements

Nothing about a PCR business matters until it is allowed to report a result. Accreditation is not paperwork you bolt on at the end; in a clinical lab you cannot bill a payer until you pass inspection, so the timeline and cost of accreditation belong in the funding model from day one.

United States

• CLIA Certificate of Compliance or Accreditation, high-complexity: PCR is classified high-complexity molecular testing, administered by CMS with the FDA and CDC. It mandates a qualified laboratory director, documented quality control, CMS-approved proficiency testing, and biennial inspection. Build cost commonly $15K–$90K; expect 3–9 months including inspection.
• CAP accreditation: the College of American Pathologists offers a deemed-status alternative many reference labs use; several thousand dollars per year plus inspection.
• State clinical-lab licence: New York (CLEP) and California are the strictest and can add up to 12 months, so factor state choice into the launch plan.
• FDA pathway: any lab-developed test you intend to commercialise as an IVD may require FDA review.

United Kingdom

• UKAS accreditation to ISO 15189:2022: the medical-laboratory standard awarded by the United Kingdom Accreditation Service, covering virology, microbiology, genetics, and point-of-care testing. The 2012-to-2022 transition deadline was December 2025. UKAS assessment fees scale with scope; a multi-site UKAS assessment budget seen in public procurement reached up to £132,000 over 2026–2028.
• MHRA registration and IVDR / Common Specification compliance: required for in-house ("laboratory-developed") tests, with the lab responsible for validating performance for its own patient population.
• CQC registration: needed if you provide a diagnostic service directly to patients; annual fee scales with size, typically 8–12 weeks to register.

International

• EU: IVDR (Regulation 2017/746) conformity, notified-body involvement for higher-risk device classes, and ISO 15189 accreditation per member state.
• Canada: Health Canada IVD device licence plus provincial lab accreditation (for example IQMH in Ontario).

Per-Test Economics & Margins

PCR revenue is a volume-times-reimbursement game with a stubborn reagent cost underneath it. Clinical molecular assays reimburse roughly $35–$150 each; the SARS-CoV-2 PCR code (CPT 87635) carries a Medicare rate of $51.31, and several commercial payers align to that figure. High-value panels (respiratory, sexually transmitted infection, oncology) bill $150–$1,200. Most operators stop at "the market is large"; the number that actually drives this business is net reimbursement per test minus reagent cost per reaction, multiplied by realistic daily throughput.

Where the money comes from

• Clinical diagnostic testing: per-test payer reimbursement, the largest line for an accredited lab.
• Reagents and consumables resale or kitting: recurring B2B revenue that mirrors the 85% consumable share of the wider market.
• Contract research (CRO) and validation services: fee-for-service qPCR/dPCR runs for biotech and academic clients.
• Specialty and send-out panels: higher-margin oncology, genetics, and infectious-disease panels once the lab is accredited.

Gross margins of 45–70% are achievable on high-throughput clinical PCR; net margins land at 8–22% after staffing, quality control, and reimbursement haircuts. The lever is utilisation: an idle thermocycler still depreciates and a salaried technologist is paid whether 30 or 130 samples run.

PCR Market Size & Demand

The global PCR market was worth $10.75B in 2025 and is projected to reach $22.81B by 2034 at an 8.75% CAGR, per Fortune Business Insights, 2026. North America led with a 39.50% share worth $4.24B in 2025. A separate estimate from The Insight Partners, 2024 puts the PCR technologies market at $24.52B by 2030, so the directional read is consistent across analysts even where base figures differ by methodology.

Two structural trends shape demand. First, real-time PCR is the workhorse, at about 62.78% of the market in 2026, while digital PCR is the fastest-growing segment because absolute quantification opens oncology, liquid-biopsy, and cell-and-gene-therapy QC work that qPCR cannot serve as cleanly. Second, infectious-disease testing is the single largest application at roughly 40.98%, so a lab that diversifies beyond respiratory panels into STI, oncology, and food/water testing smooths the post-pandemic demand cliff that caught COVID-era operators. The UK and EU markets are smaller in absolute terms but carry the same accreditation-gated structure, which favours operators who treat compliance as a moat rather than a cost.

The competitive reality is also worth stating plainly in the plan. The instrument layer is concentrated among a handful of global players (Thermo Fisher, Bio-Rad, QIAGEN, Roche, Agilent), and a new lab will buy from them, not compete with them. The competition a new lab actually faces is other testing providers: large national reference labs with procurement scale and embedded hospital relationships, regional independents competing on turnaround and service, and hospital in-house labs that may insource certain panels. A new entrant rarely wins on price against national scale, so the defensible positions are speed, a specialist panel menu, responsiveness to a defined catchment, and a CRO offer the big labs treat as an afterthought. Reagents and consumables are about 85.63% of total market revenue, which tells you where the recurring spend goes and why second-sourcing and volume-based reagent pricing are strategic, not clerical, decisions.

For UK founders, the demand picture is shaped by the NHS as both the dominant buyer and a competitor through its own pathology networks, so private PCR labs typically target private clinics, occupational health, fertility, genetics, and CRO work rather than competing head-on for NHS volume. That positioning choice belongs in the market section because it determines the entire revenue model.

Who Buys PCR Testing, and Why It Matters

A PCR business does not sell to "the public." It sells to a small number of well-defined buyers, each with a different purchase trigger, sales cycle, and willingness to pay. The plan should name them and size them, because the customer mix decides the whole operating model: a lab built for hospital send-outs looks nothing like a lab built for biotech contract research.

• Clinicians and hospital networks: order diagnostic panels (respiratory, STI, gastrointestinal, oncology) and care most about turnaround time, accreditation, and a clean interface into their electronic records. They buy through reference-lab contracts and rarely switch once a workflow is embedded, which makes them high-retention but slow to win.
• Payers and self-pay patients: the entity that actually pays the bill. Reimbursement rules, prior-authorisation friction, and per-test rates (the SARS-CoV-2 code reimburses $51.31 under Medicare) determine realised revenue, so payer contracting belongs in the marketing plan, not just the finance tab.
• Biotech, pharma, and academic CRO clients: pay fee-for-service for validated qPCR and dPCR runs, assay development, and quality-control testing for cell-and-gene therapy. Higher margin, project-based, and reachable without clinical accreditation, which is why many labs use CRO work to fund the runway to CLIA.
• Food, water, and veterinary buyers: a separate vertical with its own standards (for example ISO 22174 for food-chain PCR) and far lighter clinical regulation, useful for diversifying away from human-diagnostics reimbursement risk.

The strongest plans quantify how many of each buyer exist in the catchment, what each is worth per year, and which segment converts first. A lab that wins three regional clinics and one biotech CRO contract in year one has a far more bankable forecast than one promising a vague slice of a $10.75B global market.

Operations: Turning Samples Into Reportable Results

Operations is where a PCR lab earns or loses its margin. The single biggest controllable variable is throughput per technologist per shift, because nearly all the cost base is fixed once the lab is built. A thermocycler depreciates whether it runs 30 or 130 samples, and a qualified technologist is salaried regardless of volume. The plan should therefore model a throughput ramp, not a flat annual average, and show the milestones that lift utilisation month by month.

The contamination problem, and why workflow design is a financial issue

PCR amplifies tiny amounts of nucleic acid into millions of copies, which makes it exquisitely sensitive and exquisitely vulnerable to carry-over contamination. A single stray amplicon can produce false positives that fail proficiency testing and, in a clinical setting, harm patients. This is why a credible operations section commits to a unidirectional workflow: physically separate rooms or hoods for reagent preparation, sample preparation, and amplification, with staff and air moving one way only. Cutting that corner to save fit-out cost is the most expensive saving a founder can make, because it shows up later as failed runs, wasted reagents, and a re-validation bill.

Year-one operating priorities

• Validate each assay against the lab's own patient population before going live, since both CLIA and UKAS hold the lab, not the kit manufacturer, responsible for performance.
• Define owner-level KPIs: tests per technologist-day, reagent cost per reaction, turnaround time, repeat-test rate, and gross margin per panel.
• Stand up the LIMS and instrument integration early so chain of custody and reporting are audit-ready before the first inspection, not retrofitted under pressure.
• Build a second-source plan for critical consumables so a single vendor stockout cannot halt billing.

For most PCR labs, the gap between an average operator and a high-performing one comes down to scheduling discipline, batch sizing, and how quickly a failed control is caught and corrected. Those are operational habits, and lenders read the operations section to judge whether the founder understands that the science is the easy part.

How a PCR Lab Actually Wins Customers

Diagnostics is a trust-and-contract sale, not an impulse purchase. The go-to-market plan should connect specific channels to specific buyer types and tie each to a cost of acquisition and a sales-cycle length, so the revenue ramp is grounded in a real pipeline rather than optimism.

• Clinical referral and payer contracting: direct relationships with clinics, hospital procurement, and payer networks. Long cycle, high lifetime value, and the foundation of a clinical lab's revenue.
• B2B and CRO outreach: targeted business development to biotech and academic groups needing validated runs, often the fastest path to early cash because it sidesteps payer friction.
• Search-led inbound: capturing high-intent queries from operators and partners researching molecular testing, then converting them with proof of accreditation and turnaround.

A stronger plan ties these channels to conversion rate, contract value, and the payback period on business-development effort, and shows which channel is expected to convert first. For a capital-intensive lab, the order matters: CRO and self-pay work that can start the moment the bench is validated buys time to land the slower, larger clinical contracts.

PCR Terms Investors Will Expect You to Use Correctly

• qPCR (real-time PCR): measures DNA/RNA amplification as it happens against a standard curve; the routine workhorse, about 62.78% of the market in 2026.
• dPCR / ddPCR (digital / droplet digital PCR): partitions a sample into thousands of micro-reactions and counts positives for absolute quantification without a standard curve; the fastest-growing segment.
• Master mix: the pre-formulated reagent blend (polymerase, nucleotides, buffer) added to each reaction; a major recurring consumable cost.
• Amplicon: the amplified DNA product of a PCR reaction, and the source of carry-over contamination if workflow is not controlled.
• Limit of detection (LoD): the lowest target concentration a test reliably detects; a key validation metric regulators scrutinise.
• LIMS: Laboratory Information Management System, the software backbone for results, chain of custody, and audit-ready reporting.
• Laboratory-developed test (LDT): an in-house assay; carries FDA (US) and IVDR/MHRA (UK/EU) obligations the lab owns directly.

Questions Founders Ask

How is qPCR different from digital PCR for a commercial lab?

qPCR (real-time PCR) measures amplification as it happens and reports relative quantity against a standard curve; it is cheaper per reaction, higher throughput, and the right choice for routine infectious-disease testing. Digital PCR partitions the sample into thousands of micro-reactions and counts positives directly, giving absolute quantification without a standard curve. dPCR costs more per run but wins for low-abundance targets (residual disease, liquid biopsy, viral load near the limit of detection) and for gene-and-cell-therapy quality control. Most labs start qPCR-first and add dPCR once a paying use case justifies the instrument.

What certifications does a PCR lab need in the US and UK?

In the US, a clinical PCR lab needs a CLIA high-complexity certificate (CMS), usually paired with CAP accreditation, plus any state licence (New York and California are strictest). In the UK, the equivalent is UKAS accreditation to ISO 15189:2022, with MHRA and IVDR obligations for in-house tests and CQC registration if you serve patients directly. Research-only labs that never report a clinical result face a lighter bar but still need quality systems if they want to sell validated services.

How long before a PCR lab can start billing?

Plan for 3–9 months in the US from build-out to passing CLIA inspection, longer if you need a New York state licence. In the UK, UKAS accreditation commonly takes 6–12 months. The funding model has to carry payroll, rent, and reagent stock through that pre-revenue window, which is the most common reason underfunded labs stall.

Can you start small and scale a PCR business?

Yes. A lean path launches as a research or contract-testing service on a single qPCR platform, builds validated assays and client volume, then invests in accreditation and dPCR once recurring revenue covers the fixed base. The phased approach keeps the opening raise near the $180K floor rather than the $1.2M ceiling.

Mistakes That Sink PCR Startups

• Treating PCR as one market. Clinical diagnostics, research/CRO, food and water, and veterinary testing have different regulators, buyers, and reimbursement. Pick a beachhead vertical and write the plan for it.
• Underbudgeting accreditation and validation. The lab cannot bill until it passes CLIA or UKAS inspection. Founders who treat accreditation as a launch-week task run out of cash in the pre-revenue window.
• Vendor lock-in on consumables. Building around one platform's proprietary reagents is convenient until the consumable bill (85% of market revenue is consumables) erodes the margin. Qualify a second source for critical reagents.
• Modelling COVID-era reimbursement. Per-test rates and volumes have normalised. Build the forecast on today's blended payer mix and per-test haircuts, not 2021 numbers.
• Hiring before securing a qualified director. CLIA high-complexity status requires a qualified laboratory director. Recruit that role first; technologists without a director cannot legally report results.

A Realistic Launch Timeline

Because a clinical PCR lab cannot bill until it passes inspection, the timeline is not a nice-to-have appendix; it is the spine of the cash-flow model. The sequence below reflects how a US clinical lab typically reaches first revenue, and why the funding ask has to cover several months of cost before a single test is reimbursed.

• Months 0–2: entity formation, lab lease, instrument quotes, and the single most important early hire, a qualified laboratory director, since CLIA high-complexity status legally depends on it.
• Months 2–4: fit-out of unidirectional clean zones, instrument installation and calibration, LIMS configuration, and procurement of opening reagent stock.
• Months 4–6: assay validation against the lab's own sample types, proficiency-testing enrolment, and writing the quality manual the inspector will read line by line.
• Months 6–9: CLIA application, inspection, and, where required, a state licence (New York and California can extend this materially). Billing begins only once the certificate is issued.
• Months 9–12: ramp utilisation toward break-even by adding contracted clinics and CRO clients, with a target of crossing break-even around month 11 in the worked model below.

A research-only or food-and-water lab can compress this dramatically, since it skips clinical accreditation, which is exactly why a phased launch (CRO and self-pay first, clinical accreditation second) is the lower-risk path for an undercapitalised founder. The template's financial model lets you slide that accreditation date and watch the funding requirement move with it.

Sample Business Plan Preview

Preview the structure and financial outputs a buyer receives. These visual mockups are generated from the same assumptions used throughout this page.

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for a PCR and molecular-diagnostics venture:

• Executive Summary — your lab at a glance, written to hook a diagnostics lender or investor in 60 seconds
• Company Overview — legal structure, ownership, lab location, and founding story
• Industry Analysis — PCR market size, qPCR vs dPCR mix, and the regulatory picture
• Customer Analysis — clinicians, payers, biotech CRO clients, and the buyers behind each test type
• Competitor Analysis — reference labs, hospital labs, and platform vendors, plus your differentiation
• Marketing Plan — referral channels, payer contracting, and B2B acquisition strategy
• Operations Plan — unidirectional workflow, accreditation milestones, staffing, and throughput KPIs
• Management Team — laboratory director, technologist roster, and advisory board

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, per-test unit economics, and startup capital requirements.

Frequently Asked Questions

Related Templates & Resources

Explore more free business plan resources and adjacent industry templates from Avvale.

• Free business plan templates library
• Market research & content for your plan
• Medical laboratory business plan template
• Work with an Avvale business plan writer